Sato, Yuka
Feig, Daniel I.
Stack, Austin G.
Kang, Duk-Hee
Lanaspa, Miguel A.
Ejaz, A. Ahsan
Sánchez-Lozada, L. Gabriela
Kuwabara, Masanari
Borghi, Claudio
Johnson, Richard J. http://orcid.org/0000-0003-3312-8193
Article History
Accepted: 12 June 2019
First Online: 11 July 2019
Competing interests
: A.G.S. has had an unrestricted educational grant from the Menarini International Operations Luxemburg and has consulted for Menarini and Grunenthal Pharma. L.G.S.-L has received funding from Relburn Metabolomic and Danone Research Foundation. R.J.J. has equity with XORT Therapeutics, which is developing novel xanthine oxidase inhibitors and is an inventor involved in several patents on the role of uric acid in hypertension, metabolic syndrome and diabetic nephropathy that have resulted from his research (US Patent No. 7,799,794; US Patent No. 8,236,488; US Patent No. 8,557,831; US Patent No. 9,155,740B). He has also consulted for Danone Research Foundation, for Horizon Pharmaceuticals and for AstraZeneca. The other authors declare no competing interests.